DNAzyme-mediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in Escherichia coli

Yamei Liu, Victor G Stepanov, Ulrich Strych, Richard C Willson, George W Jackson, George E Fox

Abstract

Background: Manufacturing large quantities of recombinant RNAs by overexpression in a bacterial host is hampered by their instability in intracellular environment. To overcome this problem, an RNA of interest can be fused into a stable bacterial RNA for the resulting chimeric construct to accumulate in the cytoplasm to a sufficiently high level. Being supplemented with cost-effective procedures for isolation of the chimera from cells and recovery of the recombinant RNA from stabilizing scaffold, this strategy might become a viable alternative to the existing methods of chemical or enzymatic RNA synthesis.

Results: Sequence encoding a 71-nucleotide recombinant RNA was inserted into a plasmid-borne deletion mutant of the Vibrio proteolyticus 5S rRNA gene in place of helix III - loop C segment of the original 5S rRNA. After transformation into Escherichia coli, the chimeric RNA (3xpen arRNA) was expressed constitutively from E. coli rrnB P1 and P2 promoters. The RNA chimera accumulated to levels that exceeded those of the host’s 5S rRNA. A novel method relying on liquid-solid partitioning of cellular constituents was developed for isolation of total RNA from bacterial cells. This protocol avoids toxic chemicals, and is therefore more suitable for large scale RNA purification than traditional methods. A pair of biotinylated 8-17 DNAzymes was used to bring about the quantitative excision of the 71-nt recombinant RNA from the chimera. The recombinant RNA was isolated by sequence-specific capture on beads with immobilized complementary deoxyoligonucleotide, while DNAzymes were recovered by biotin affinity chromatography for reuse.

Conclusions: The feasibility of a fermentation-based approach for manufacturing large quantities of small RNAs in vivo using a “5S RNA scaffold” strategy is demonstrated. The approach provides a route towards an economical method for the large-scale production of small RNAs including shRNAs, siRNAs and aptamers for use in clinical and biomedical research.

Background

In recent years, small RNAs, including siRNAs (small interfering RNAs), shRNAs (small hairpin RNAs), aptamers, and ribozymes [1-9] have attracted increasing interest for their fundamental role in gene regulation, as well as for the potential of their use as novel diagnostic and therapeutic agents [10-16]. Interfering RNAs have generated particular interest due to its ability to effectively silence genes. For example, large-scale RNAi screens have been conducted to identify important genes in various biological pathways [17]. Multiple siRNA-based therapies are currently under development and soon may be used in the treatment of diseases such as hepatitis virus infection, macular degeneration, leukemia, and acquired immune deficiency syndrome [18-21]. Likewise, due to their high affinity and relatively low cost, aptamers have been used in numerous investigations seeking novel diagnostic tools or new drugs [7,22-25]. For example, an anticoagulant RNA aptamer that specifically binds and inactivates Factor IXa, is currently in Phase II clinical trials [23,26]. With the expanding use of small RNAs in basic and applied biological research, the demand for large quantities of synthetic RNAs of high quality has dramatically increased.
Traditional methods of chemical and enzymatic synthesis are effective but are currently very expensive when large amounts are needed. Thus, a cost-effective method to produce defined small RNAs in large quantities is urgently needed.

The in vivo expression of recombinant RNAs has been described for some time [27-29]. However, the heterogeneity of the RNA products and their instability in the cytoplasm due to cleavage by cellular ribonucleases (RNases) have made the process inefficient. For example, mRNAs expressed in E. coli from T7 promoter exhibit a substantial heterogeneity due to ambiguous termination of the RNA transcripts [28,29]. Attempts to obtain in vivo expression of aptamers also were not successful, apparently because the resulting transcripts were again heterogeneous and did not accumulate to any substantial level [30]. One way to overcome these limitations is by expressing RNA molecules of interest in a tRNA scaffold [30,31]. In one such study, the epsilon sequence of human hepatitis B virus (HBV) was inserted into cloning sites surrounded by a tRNALys or tRNAMet scaffold under the control of E. coli lpp promoter. The tRNA scaffold formed a structure that protected the RNA insert from nucleolytic digestion. The tRNA-HBV chimera was shown to be successfully expressed in E. coli and could be extracted by affinity capture when the chimeric RNA contained in addition a sephadex or streptavidin aptamer module. The RNA insert was released from the tRNA scaffold using the enzyme RNase H and two unmodified guide deoxyoligonucleotides. However, the reported absolute positional specificity of RNA cleavage by RNase H is uncommon under the described conditions [32-34], and cannot be regarded as a general case. In addition, it is not yet known if a large variety of RNAs can be successfully prepared with this system or how the presence of the construct may affect the host cell.

Herein, a fermentation-based system for expressing and purifying functional RNAs, especially RNAs of less than 100 nucleotides, is described. In this system, RNA sequences of interest are expressed under the strong P1 and P2 ribosomal promoters from the E. coli rrnB operon in the context of a carrier derived from 5S rRNA [35]. The resulting RNA product does not enter the ribosome but nevertheless accumulates to levels comparable to those of wild type 5S rRNA. In previous work with this system, various RNA insert sequences were incorporated into the plasmid-encoded 5S rRNA scaffold [36,37]. In each case, the expressed RNA/insert chimeras accumulated to high levels in the cell. An examination of the transcriptome revealed that the presence of the insert had essentially no effect on gene expression in the host cell [38]. In order for this approach to be broadly applicable, however, it will be necessary to extract the RNA of interest from the 5S rRNA carrier. We demonstrate herein that this can be effectively accomplished using sequence-specific DNAzymes [39-43]. An RNA substrate known as the 3×pen aRNA [37] (Figure 1) is used as a model system. The insert in this case is highly structured, as are many of the RNAs of interest and, at 71 nucleotides, illustrates that relatively large RNAs can be expressed in the 5S rRNA carrier system with good success.

Methods
Chemicals
Enzymes were purchased from Promega (Madison, WI) or New England Biolabs (Ipswich, MA). Synthetic deoxyoligonucleotides (Table 1) were obtained from Eurofins MWG (Huntsville, AL) and IDT (Coralville, IA). DNA markers were purchased from NEB and Bionexus (Oakland, CA). Chemicals were obtained from Sigma (St. Louis, MO) and EMD Chemicals (Gibbstown, NJ).

RNA expression scaffold
Plasmid pCP3×3 [37] was electroporated into E. coli JM109 (DE3) (Promega) and used as the RNA expression scaffold in this work. The core element of the plasmid is the truncated 5S rRNA gene from Vibrio proteolyticus with a 71-nt insertion sequence. Gene expression is controlled by the E. coli rrnB P1 and P2 promoters. 3×pen aRNA coding sequence is followed by the E. coli rrnB T1 and T2 transcription terminators.

![Figure 1 Sequence and predicted secondary structure of 3xpen aRNA (160 nt).](http://www.biomedcentral.com/1472-6750/10/85)
Table 1 Sequences and modifications of deoxyoligonucleotides used in this study

| Name of oligos  | Sequence (from 5’ to 3’) | Length (nt) |
|----------------|--------------------------|-------------|
| Pen17zyme1     | GCTAATTGGTTAAGGGCCGTCGAAAGCTAACATGAGTTTTAC | 41 |
| Pen17zyme1B    | GCTAATTGGTTACGGCCGACACGAATACATGAGTTTTAC    | 44 |
| Pen17zyme1C    | GCTAATTGGTTACGGCCGACACGAATACATGAGTTTTAC    | 45 |
| Pen17zyme2     | GAGTTTTACGGTTATGTACCACTACGACACAGAAGCTAACATGAGTTTTAC | 44 |
| bioPEN17zyme1B | Biotin-GCTAATTGGTTACGGCCGACACGAATACATGAGTTTTAC | 44 |
| bioPEN17zyme2  | Biotin-GAGTTTTACGGTTATGTACCACTACGACACAGAAGCTAACATGAGTTTTAC | 44 |
| bioantiPEN     | Biotin-GAGTTTTACGGTTATGTACCACTACGACACAGAAGCTAACATGAGTTTTAC | 32 |

*Underlined bold letters indicate residues that comprise the catalytic core of each DNAzyme.*

Isolation of small RNAs from *E. coli*

Cells were grown at 37°C in LB medium with constant shaking (250 rpm). 100 μg/ml ampicillin was added to plasmid-carrying cells. Cell growth (OD600) was monitored using a Labomed Spectro SC spectrophotometer. After incubation, cells were collected by centrifugation (30 min, 5000 × g, 4°C). The resulting (typically 200 mg) pellet was resuspended in 960 μl of 10 mM Tris-HCl (pH 7.5). Cells were lysed by adding 160 μl of 1 M Tris-Acetate with 0.1 M EDTA (pH 7.5), 160 μl of 10% SDS and 320 μl of pure formamide. After 20 min shaking at 37°C, 1.6 ml of 3 M potassium acetate (pH 4.8) was added, and the mixture was shaken gently for another 10 min. Cell debris and precipitated material were removed by centrifugation (20 min, 10000 × g, 4°C). The cleared supernatant was recovered and mixed with 8 ml of ethanol. After 1 h incubation at -80°C, the precipitated nucleic acids were collected by centrifugation (20 min, 10000 × g, 4°C). The pellet was then resuspended in 300 μl of 3 M sodium acetate (pH 5.0), and was shaken at 37°C for 10 min to selectively solubilize the small RNAs. Insoluble material was removed by centrifugation (20 min, 10000 × g, 4°C), and the supernatant was mixed with 750 μl of ethanol. Finally, the precipitate containing mostly small RNAs was collected by centrifugation (20 min, 10000 × g, 4°C), washed twice with 70% ethanol, and air dried for 15 min. Dry RNA pellets were dissolved in water, and their concentration was determined spectrophotometrically.

Cleavage with DNAzymes

The DNAzymes used for the excision of RNA fragments from the 5S rRNA scaffold are listed in Table 1. The reaction conditions screened during optimization of 3×*pen* aRNA cleavage are summarized in Table 2. DNAzymes were annealed to the 3×*pen* aRNA substrate in 50 mM MOPS-NaOH (pH 7.2) containing additional components as specified in Table 2, at 90°C for 2 min, and then cooled to 23°C over 10 min in a thermal cycler (Eurofins-MWG). After annealing, the mixture of DNAzymes and aRNA was adjusted to contain 125 mM KCl, 500 mM NaCl, 7.5 mM MgCl2, MnCl2 (up to 45 mM), and 50 mM MOPS (pH 7.2) besides the indicated additional components, and incubated at 23°C or 40°C for up to 72 hours. In reaction 16 and 23, 50 and 6 additional cycles were introduced, respectively. After the incubation, the reaction was terminated by adding 0.1 vol. 3 M sodium acetate (pH 5.0). The reaction products were recovered by ethanol precipitation and analyzed by denaturing PAGE. The intensity of bands in these reactions was plotted using the ‘profile’ function of ImageJ [46], and the total cutting percentage was quantified as P = 1 - [intact 3×*pen* aRNA]/[total 3×*pen* aRNA]. Similarly, ImageJ was used to determine the yield of final product relative to the starting amount of chimeric aRNA per wet cell paste.

Isolation of 5’-biotinylated DNAzymes and RNA Fragments by Affinity Capture

Biotinylated DNAzymes were removed from the mixture of cleavage reaction products using streptavidin agarose beads (Molecular Probes, Eugene, OR) in 3× NTE buffer.
The DNAzymes were recovered from the beads by heating in H2O at 65°C. The excised RNA fragments were isolated by affinity capture through hybridization to a complementary oligodeoxyribonucleotide, bioanti-PEN (Table 1), immobilized on streptavidin agarose beads via streptavidin-biotin linkage [47].

### Table 2: Conditions of 3×pen aRNA cleavage evaluated during optimization of the reaction yield

| Reaction No. | [3×pen aRNA] (μM)* | Molar ratio 3×pen aRNA: Pen17zyme1B/IC: Pen17zyme2 | Additional components in the annealing buffer | [Mn²⁺] (mM)* | Reaction T (°C) | Time Additional Cycles |
|--------------|--------------------|-------------------------------------------------|-----------------------------------------------|--------------|-----------------|------------------------|
| 1            | 0.25               | 1:0:1                                           | N/A                                           | 0            | 23              | 10 min 0               |
| 2            | 0.25               | 1:0:1                                           | N/A                                           | 7.5          | 23              | 10 min 0               |
| 3            | 0.25               | 1:0:1                                           | N/A                                           | 15           | 23              | 10 min 0               |
| 4            | 0.25               | 1:0:1                                           | N/A                                           | 45           | 23              | 10 min 0               |
| 5            | 0.25               | 1:0:1                                           | N/A                                           | 15           | 23              | 100 min 0              |
| 6            | 0.25               | 1:1(Pen17zyme1B):0                              | N/A                                           | 15           | 23              | 100 min 0              |
| 7            | 0.25               | 1:1(Pen17zyme1B):0                              | N/A                                           | 15           | 23              | 100 min 0              |
| 8            | 0.25               | 1:1(Pen17zyme1C):0                              | N/A                                           | 15           | 23              | 100 min 0              |
| 9            | 0.25               | 1:5(Pen17zyme1B):0                              | N/A                                           | 15           | 23              | 100 min 0              |
| 10           | 0.25               | 1:1(Pen17zyme1B):0                              | N/A                                           | 15           | 23              | 17 h 0                 |
| 11           | 0.25               | 1:1(Pen17zyme1B):0                              | N/A                                           | 15           | 40              | 100 min 0              |
| 12           | 0.25               | 1:1(Pen17zyme1B):0                              | 10% EtOH                                      | 15           | 23              | 100 min 0              |
| 13           | 0.25               | 1:5(Pen17zyme1B):0                              | 0.3 M KCl, 1.2 M NaCl                         | 15           | 23              | 17 h 0                 |
| 14           | 0.25               | 1:5(Pen17zyme1B):0                              | 20% PEG 8000                                 | 15           | 23              | 17 h 0                 |
| 15           | 0.25               | 1:5(Pen17zyme1B):0                              | 500 μM spermine                              | 15           | 23              | 17 h 0                 |
| 16           | 0.25               | 1:5(Pen17zyme1B):0                              | N/A                                           | 15           | 23              | 17 h 50                |
| 17           | 0.25               | 1:5(Pen17zyme1B):0                              | 2.2 M potassium acetate                      | 15           | 23              | 17 h 0                 |
| 18           | 0.25               | 1:5(Pen17zyme1B):0                              | 3 M LiCl                                      | 15           | 23              | 17 h 0                 |
| 19           | 0.80               | 1:10(Pen17zyme1B):1                             | 500 μM spermine                              | 15           | 23              | 17 h 0                 |
| 20           | 0.80               | 1:10(Pen17zyme1B):1                             | 500 μM spermine                              | 15           | 23              | 17 h 0                 |
| 21           | 0.80               | 1:20(Pen17zyme1B):2                             | 500 μM spermine                              | 15           | 23              | 17 h 0                 |
| 22           | 0.80               | 1:10(Pen17zyme1B):10                            | 500 μM spermine                              | 15           | 23              | 17 h 0                 |
| 23           | 0.80               | 1:10(Pen17zyme1B):10                            | 500 μM spermine                              | 15           | 23              | 17 h 6                 |
| 24           | 0.80               | 1:10(Pen17zyme1B):10                            | 500 μM spermine                              | 15           | 23              | 40 h 0                 |
| 25           | 0.80               | 1:10(Pen17zyme1B):10                            | 500 μM spermine                              | 15           | 23              | 72 h 0                 |
| 26           | 0.80               | 1:10(bioPen17zyme1B):10(bioPen17zyme2)          | 500 μM spermine                              | 15           | 23              | 72 h 0                 |

* The value corresponds to the final concentration of the indicated component in the reaction mixture.

(0.6 M NaCl, 15 mM Tris-HCl, 7.5 mM EDTA, pH 7.5) [47]. The DNAzymes were recovered from the beads by heating in H2O at 65°C. The excised RNA fragments were isolated by affinity capture through hybridization to a complementary oligodeoxyribonucleotide, bioanti-PEN (Table 1), immobilized on streptavidin agarose beads via streptavidin-biotin linkage [47].

### Results and Discussion

#### Expression of 3×pen aRNA in strain JM109 (DE3)

The 160-nt 3×pen aRNA was strongly expressed in *E. coli* (Figure 2 and Figure 3A, Lane 1). The ratio of 3×pen aRNA to 5S rRNA after 8 and 24 h of incubation was 1.07 and 0.46, respectively, as determined by electrophoresis and imaging as described above. Thus, the
accumulation of 3×pen aRNA after an 8-hour incubation slightly exceeded that of native 5S rRNA but subsequently declined, suggesting selective degradation of the recombinant RNA over time. Isolation of 3×pen aRNA from 8-hour bacterial cultures routinely yielded 2.5 - 2.6 mg of the chimeric RNA from 1 g of wet cells.

Excision of specific small RNA using DNAzymes
In order to optimize the cleavage reaction, multiple reaction conditions were examined (Table 2) by varying DNAzymes, RNA substrate to DNAzymes ratio, additives, Mn$^{2+}$ concentration, reaction temperature, and incubation time. In some cases, alternating denaturation and renaturation cycles were introduced to examine whether this increased the overall yield of the desired RNA products. Equal amounts of 3×pen aRNA were used in each reaction condition, and the reaction products were analyzed by denaturing PAGE. Four DNAzymes (Pen17zyme1, -1B, -1C and -2) were investigated for their ability to excise small RNAs from the 5S rRNA expression scaffold. Their predicted excision sites on the 3×pen aRNA are shown in Figure 1, and cleavage at these two sites was expected to produce a 71-nt product. As revealed by electrophoresis, the overall yield of the desired RNA products was higher with Pen17zyme1B than with Pen17zyme1, while Pen17zyme1C was found to be inactive (Figure 2). Thus, Pen17zyme1B, which cleaves GA dinucleotides, and Pen17zyme2, which cleaves GG dinucleotides (Figure 1), were used in subsequent cleavage reactions. Additionally, the 5′-biotinylated DNAzymes were found to cleave with equal efficiency as their unmodified forms, and the expected 71-nt product was obtained likewise by cleavage reactions using 5′-biotinylated bioPen17zyme1B and bioPen17zyme2 (Figure 4, Lane 3). Intensity of the 3×pen aRNA band on the polyacrylamide gel (Figure 3) decreased when the concentration of Pen17zyme1B and Pen17zyme2 increased in the reaction mixtures, indicating that 3×pen aRNA was being efficiently cleaved by these DNAzymes. Complete excision was achieved after 72 h incubation at 23°C and a molar ratio of [3×pen aRNA]: [Pen17zyme1B]: [Pen17zyme2] of 1:10:10 (Table 3).

In most cases, the presence of additional components in the annealing buffer including ethanol, PEG 8000, potassium acetate, LiCl and increased concentrations of KCl or NaCl did not affect the overall yield of the desired RNA product. However, the addition of 500 μM spermine improved the total cutting percentage significantly. It is thought that the spermine may stabilize the DNAzyme/RNA hybrids [48]. Spermine-mediated stabilization of DNA helices [49] and DNA-RNA hybrids [50,51] has been extensively reported in the literature. Previous studies of DNAzymes have shown that substrate cleavage required divalent metal cations such as Mg$^{2+}$, Ca$^{2+}$ or Mn$^{2+}$ [52-55]. Here, the effects of four different Mn$^{2+}$ conditions (0, 7.5, 15 and 45 mM) were tested. We confirmed that in the absence of Mn$^{2+}$, essentially no cleavage was seen and that the highest total cutting percentage was observed at 15 mM Mn$^{2+}$. With respect to the reaction temperature, it was found that 23°C was superior to 40°C in producing efficient RNA processing (data not shown). Introducing denaturation/renaturation cycles into the reaction did not improve the overall yield of the desired RNA products. Perhaps not surprisingly, it was also found that longer incubation time greatly improved the total cutting percentage when the same concentration of DNAzymes was added in the reaction mixture (Table 3).
Figure 3 3×pen aRNA cleavage by Pen1zyme1B and Pen1zyme2. Cleavage reaction products were analyzed on denaturing 8% PAGE. Incubation of 3×pen aRNA (160 nt) with the Pen1zyme1B and Pen1zyme2 resulted in accumulation of 71-nt final excision product and 137-nt semi-product. (A) Lane 1, total RNA from E. coli JM109(DE3)/pCP3×3 enriched for low molecular weight RNAs (total RNA); Lane 2, low molecular weight DNA ladder (LWM); Lane 3, 3×pen aRNA; Lanes 4-6, Cleavage products of 3×pen aRNA after 17 hours of incubation with 3×pen aRNA: Pen1zyme1B: Pen1zyme2 molar ratio 1:1:1, 1:10:1, and 1:10:2, respectively. (B) Lane 1, total RNA; Lane 2, LWM; Lane 3, 3×pen aRNA; Lane 4, Cleavage products of 3×pen aRNA after 40 hours of incubation with 3×pen aRNA: Pen1zyme1B: Pen1zyme2 molar ratio 1:10:1. (C): Lane 1, total RNA; Lane 2, LWM; Lane 3, 3×pen aRNA; Lane 4, Cleavage products of 3×pen aRNA after 40 hours of incubation with 3×pen aRNA: Pen1zyme1B: Pen1zyme2 molar ratio 1:10:10. (D): Lane 1, LWM; Lane 2, total RNA; Lane 3, equimolar mixture of Pen1zyme1B and Pen1zyme2; Lane 4, 3×pen aRNA; Lane 5, Cleavage products of 3×pen aRNA after 72 hours of incubation with 3×pen aRNA: Pen1zyme1B: Pen1zyme2 molar ratio 1:10:10. Cleavage reactions were performed under conditions described in legend to Figure 2 except for the incubation time and 3×pen aRNA: DNazymes molar ratio, which were as indicated above.

Figure 4 Separation of the products of 3×pen aRNA cleavage using streptavidin agarose beads. Collected fractions were analyzed on denaturing 8% PAGE. Lane1, LWM; Lane 2, 3×pen aRNA; Lane 3, Original cleavage reaction mixture; Lanes 4-5: Isolation of biotinylated DNAzymes, first and second elutions from the beads, respectively; Lane 6: Isolation of 71-nt excision product on the beads saturated with biotinylated complementary deoxyoligonucleotide, bioantiPEN; Lane 7: Recovery of bioantiPEN from the beads. Cleavage reaction was performed for 72 hours under conditions described in legend to Figure 2, with 3×pen aRNA: bioPen1zyme1B: bioPen1zyme2 molar ratio 1:10:10.
In summary, the best conditions among those tested were as follows: (i) a substrate to enzyme molar ratio ([3×pen aRNA]:[Pen17zyme1B]:[Pen17zyme2]) of 1:10:10, (ii) denaturation and annealing in 50 mM MOPS-NaOH (pH 7.2), 500 μM spermine at 90°C for 2 min with subsequent cooling to 23°C over a period of 10 min, (iii) incubation in 125 mM KCl, 500 mM NaCl, 7.5 mM MgCl₂, 15 mM MnCl₂, 150 μM spermine, and 50 mM MOPS-NaOH (pH 7.2), at 23°C for 72 h. As suggested by Table 3, longer incubation time is likely to further improve overall yield of the desired RNA fragment.

RNA and DNAzyme Recovery by Affinity Capture

It is desirable that the isolation of the RNA product and recovery of DNAzymes avoid labor-intensive procedures. Following the cleavage reaction, the 5’-biotinylated Pen17zymes 1B and -2 were successfully removed from the reaction mixture by affinity chromatography, heat eluted (Figure 4, lane 4 & 5) and could presumably be reused in new cleavage reactions. After removal of the DNAzymes, the reaction mixture was purified by hybridization affinity capture on an immobilized oligonucleotide bioantiPEN, which is complementary to the desired RNA product. Figure 4 illustrates that the RNA eluate from the affinity matrix contained the 71-nt excised RNA fragment, indicating the expected digestion of 3×pen aRNA. The RNA product was found to be 82% pure as determined by electrophoresis and imaging as described above. The overall yield of the purified RNA fragment was 0.72 mg from 1 g of cells. However, trace amounts of deoxyoligonucleotide bioantiPEN were found in the RNA elution fraction (Figure 4, lane 6). If desired, this contamination could be easily removed by DNase treatment of the excised RNA fraction. Alternatively, this contamination could be prevented by covalent immobilization of the capture oligo on rigid supports like glass or silica.

Conclusions

The feasibility of an E. coli based in vivo expression system capable of producing small RNAs using a 5S rRNA scaffold has been demonstrated. The DNA construct is recognized as essentially a normal RNA coding region and the resulting transcript is processed into a single RNA species of defined sequence and length. The strong expression of chimeric 3×pen aRNA here and in nearly twenty other 5S rRNA/insert chimeras examined in previous studies [36,56] demonstrates that the 5S rRNA scaffold is robust and can accommodate many RNA inserts of diverse sizes.

Here, we have also described a new method for total RNA isolation. Compared to traditional RNA isolation methods such as Trizol™[57,58] or hot phenol extractions, the new method does not involve toxic chemicals. Thus, it is safer to the user, more environmentally friendly, and might be particularly advantageous for scale-up. The new method also displays some degree of desirable size selectivity, in that low molecular weight RNAs appeared to have been enriched, while the amount of larger RNAs had been reduced at the end of the RNA isolation procedure.

In addition, we demonstrated the successful excision of a 3×pen aRNA from the scaffold using 8-17 DNAzymes Pen17zyme1B and Pen17zyme2. Since DNAzymes can be readily obtained from various commercial sources, and the reaction preferentially occurs at room temperature (23°C), it constitutes an attractive method for the large scale preparation of small RNAs through fermentation of E. coli. Under best reaction conditions, nearly all the 3×pen aRNA was digested, and 90% of it was further processed to yield the desired 71-nt RNA product after 72 h. Depending on the requirements, the rate of cleavage can be manipulated by adjusting the DNAzyme-to-RNA ratio to either speed up the process or conserve DNAzymes. In an industrial environment, the priority might be given to reducing the costs of reagents vs. the reaction rate. Manufacturing processes usually involve continuous operations, and under such circumstances the time for individual reaction cycles may not be as important as the cost for labor, chemicals, and equipment.
In a further step towards improving the economical attractiveness of the method, we have shown recovery of both the RNA product and the DNAzymes through affinity chromatography. Although DNA oligomers can be chemically synthesized, the ability to readily recycle the DNAzymes will substantially reduce the cost of the whole procedure. In the present study, affinity chromatography of streptavidin agarose beads was employed to demonstrate the possibility of recovering DNAzymes. Future studies may include covalent immobilization of DNAzymes on more durable and less expensive supports such as glass or silica, which would be more compatible with industrial applications. In addition, it was shown that a longer incubation time greatly improved the overall yield of desired RNA product with equal concentration of DNAzymes in the reaction mixtures. Therefore, the cost of DNAzymes can be further reduced by trading off speed for cost.

In summary, a fermentation-based approach to large scale RNA production of functional RNAs using the 5S rRNA scaffold strategy is described. The approach combines high levels of in vivo expression, convenient purification of chimeric RNAs and cost-efficient excision of insert RNA from the chimera and therefore offers a promising alternative for large scale RNA manufacturing.

List of abbreviations
RNA: ribonucleic acid; DNA: deoxyribonucleic acid; SS rRNA: SS ribosomal RNA; mRNA: messenger RNA; tRNA: transfer RNA; DNAzyme: deoxyribozyme; RNAi: RNA interference; PEG: polyethylene glycol; PAGE: polyacrylamide gel electrophoresis; UV: ultraviolet; TLC: thin-layer chromatography; EDTA: ethylenediaminetetraacetic acid; HEPES: N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; MOPS: 3-(N-morpholino)propanesulfonic acid.

Acknowledgements
This work was funded in part by grants to GEF from the Georgia Institute of Technology Center for Ribosomal Evolution and Adaptation and the Center for Bionanotechnology and Environmental Research at Texas Southern University (NASA Cooperative Agreement NNX08B4A47A), to RCW from the NASA Cooperative Agreement NNX08B4A47A, to EAT from the Texas A&M University System Research Foundation (0738336) and National Institutes of Health (NASA Cooperative Agreement NNX08B4A47A), to RCW from the University of Houston (NASA Cooperative Agreement NNX08B4A47A), and to RCW from the Center for Ribosomal Evolution and Adaptation (0738336) and National Institutes of Health (1R41ES016478-01) to GWJ.

Author details
1Department of Biology and Biochemistry, University of Houston, Houston, TX, USA. 2Department of Chemical and Biomolecular Engineering, University of Houston, Houston, TX, USA. 3BioTex, Inc, Houston, TX, USA.

Authors’ contributions
GEF, VGS and GWJ conceived the study. YL and VGS designed and performed the experiments. US, RCW, and GWJ participated in data analysis. All authors contributed to drafting the manuscript. All authors read and approved the final manuscript.

Competing interests
GEF, VGS, GWJ, and YL have one or more pending patent applications on the described technology. This intellectual property has been licensed to BioTex, Inc.

Received: 23 July 2010 Accepted: 6 December 2010 Published: 6 December 2010

References
1. Kaur G, Roy I: Therapeutic applications of aptamers. Expert Opin Investig Drugs 2008, 17:43-60.
2. Pal S, Ellington AD: Using RNA aptamers and the proximity ligation assay for the detection of cell surface antigens. Methods Mol Biol 2009, 504:385-398.
3. Lee C, Dhillion J, Wang MY, Gao Y, Hu K, Park E, Aistanehe A, Hung MC, Eirew P, Eaves CJ, Dunn SE: Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 2008, 68:8661-8666.
4. Chu TC, Tuw KY, Ellington AD, Levy M: Aptamer mediated siRNA delivery. Nucleic Acids Res 2006, 34:e73.
5. Chalk AM, Warfinge RE, Georgi-Hemming P, Sonnhammer EL: siRNAdb: a database of siRNA sequences. Nucleic Acids Res 2005, 33 Database: D131-134.
6. Gefhardt K, Shokraei A, Babaie E, Lindqvist BH: RNA aptamers to S-adenosylhomocysteine: kinetic properties, divalent cation dependency, and comparison with anti-S-adenosylhomocysteine antibody. Biochemistry 2000, 39:7255-7265.
7. McCauley TG, Hamaguchi N, Argaraj BH: RNA interference and HIV-1 infection. Rev Med Virol 2008, 18:5-18.
8. Lea MA: Recently identified and potential targets for colon cancer treatment. Future Oncol 2010, 6:993-1002.
9. Pfeffer S, Baumert TF: Impact of microRNAs for pathogenesis and treatment of hepatitis C virus infection. Gastroenterol Clin Biol 2010, 34:281-286.
10. Barrick JE, Corbino KA, Winkler WC, Nahvi A, Mandal M, Collins J, Lee M, Roth A, Sudarshan N, Iona J, Wickiser JK, Breake RR: New RNA motifs suggest an expanded scale for riboswitches in bacterial genetic control. Proc Nadl Acad Sci USA 2004, 101:6421-6426.
11. Kanazki LI, Omelas SS, Argaraj BH: RNA interference and HIV-1 infection. Rev Med Virol 2008, 18:5-18.
12. Pfeffer S, Baumert TF: Impact of microRNAs for pathogenesis and treatment of hepatitis C virus infection. Gastroenterol Clin Biol 2010, 34:281-286.
13. Thoma C, Bogner D: Short hairpin RNAs specific to human cytomegalovirus terminase subunit D131-134. Antivir Ther 2010, 15:391-400.
14. Gebhardt K, Shokraei A, Babaie E, Lindqvist BH: RNA aptamers to S-adenosylhomocysteine: kinetic properties, divalent cation dependency, and comparison with anti-S-adenosylhomocysteine antibody. Biochemistry 2000, 39:7255-7265.
aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008, 16:66-73.

25. Sarraf-Yazdi S, Mi J, Moewer BJ, Niu X, White RR, Kontos CD, Sullenger BA, Dewhirst MW, Clay RF. Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angipoietin 2-specific RNA aptamer. J Surg Res 2008, 146:16-23.

26. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhube SR, Gelchist KC, Kleiman NS, Voichheimer DA, Chonos N, Melloni C, Alexander JH, Harrington RA, Tonikins RM, Becker RC, Rusconi CP. Phase 1b randomized study of antidote-controlled modulation of factor IX activity in patients with stable coronary artery disease. Circulation 2008, 117:2865-2874.

27. Lago BO, Bimbaum J, Demain AL. Fermentation process for double-stranded ribonuclease acid, an interferon inducer. Appl Microbiol 1972, 24:430-436.

28. Studer F, Rosenberg AH, Dunn JJ, Dubendorf JW. Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 1990, 185:89-90.

29. Lopez Pj, Dreyfus M. The lacZ mRNA can be stabilised by the T7 late mRNA leader in E. coli. Biochimie 1996, 78:408-415.

30. Ponchon L, Darde F. Recombinant RNA technology: the RNA scaffold. Nat Methods 2007, 4:571-576.

31. Ponchon L, Beaussart G, Nonin-Lecomte S, Darde F. A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protocols 2009, 4:947-959.

32. Kanaya S. Prokaryotic type 2 RNases H. Methods Enzymol 2001, 341(Pt A):377-394.

33. Inoue H, Hayase Y, Iwai S, Ohnaka E. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett 1987, 215:327-330.

34. Lima WF, Mohan V, Crooke ST. DNAzyme-mediated recovery of small RNA using modified oligonucleotide splints and RNase H. Nucleic Acids Res 2005, 33:7539-7545.

35. Pitulle C, Hedensterna KO, Fox GE. A novel approach for monitoring genetically engineered microorganisms by using artificial, stable RNAs. Appl Environ Microbiol 1995, 61:9661-9666.

36. D’Souza LM, Larios-Sanz M, Setterqust RA, Willson RC, Fox GE. Small RNA sequences are readily stabilized by inclusion in a carrier RNA. Biotechnol Prog 2003, 19:734-738.

37. Pitulle C, D’Souza L, Fox GE. A low molecular weight artificial RNA of unique size with multiple probe target regions. Syst Appl Microbiol 1997, 20:135-136.

38. Tucker DL, Kanoua F, Wang J, Luo Y, Li TB, Willson RC, Fox GE. Effect of an artificial RNA marker on gene expression in Escherichia coli. Appl Environ Microbiol 2005, 71:4156-4159.

39. Breaker RR. Natural and engineered nucleic acids as tools to explore biology. Nature 2004, 422:838-845.

40. Breaker RR. Making Catalytic DNAs. Science 2000, 290:2095-2096.

41. Breaker RR, Joyce GF. A DNA enzyme with Mg(2+)-dependent RNA phosphoesterase activity. Chem Biol 1995, 2:655-660.

42. Breaker RR, Joyce GF. A DNA enzyme that cleaves RNA. Chem Biol 1994, 1:223-229.

43. Breaker RR. DNA enzymes. Nat Biotechnol 1997, 15:427-431.

44. Blum H, Beier H, Gross H. Improved silver staining of plant-proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 1987, 8:93-99.

45. Sambojuk J, Fritsch EF, Maniatis T. Molecular cloning. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.

46. Grish V, Vijayalakshmi A. A affordable image analysis using NIH Image/ ImageJ. Indian J Cancer 2004, 41:47.

47. Rinehart J, Koot B, Rubio MA, Alfonzo JD, Soll D. Saccharomyces cerevisiae imports the cytotoxic pathway for Gln-tRNA synthesis into the mitochondrion. Genes Dev 2005, 19:583-592.

48. Antony T, Thomas T, Shirahtah A, Thomas TJ. Selectivity of polyamines on the stability of RNA-DNA hybrids containing phosphodiester and phosphorothioate oligodeoxyribonucleotides. Biochemistry 1999, 38:10775-10784.

49. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001, 58:254-288.

50. Venkteswaran S, Vijayanathan V, Shirahtah A, Thomas T, Thomas TJ. Antisense recognition of the HER-2 mRNA: effects of phosphorothioate substitution and polyamines on DNA:RNA, RNA:RNA, and DNA:DNA duplex stability. Biochemistry 2005, 44:303-312.

51. Xaplante MA, Petropoulos AD, Dinos GP, Kalpaxis DL. Localization of spermine binding sites in 23S rRNA by photoaffinity labeling: parsing the spermine contribution to ribosomal 50S subunit functions. Nucleic Acids Res 2005, 33:2792-2805.

52. Bonaccio M, Creda A, Peracchi A. Kinetic and thermodynamic characterization of the RNA-cleaving 8-17 deoxyribozyme. Nucleic Acids Res 2008, 36:2916-2925.

53. Cruz RP, Withers JB, Li Y. Dinucleotide junction cleavage versatility of 8-17 deoxyribozyme. Chem Biol 2004, 11:57-67.

54. Liu Z, Mei SH, Brennan JD, Li Y. Assembling of signaling DNA enzymes with intriguing metal-ion specificities and pH dependences. J Am Chem Soc 2003, 125:7539-7545.

55. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chlorofrom extraction. Anal Biochem 1987, 162:156-159.

56. Chomczynski P, Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat Protocols 2006, 1:581-585.

Cite this article as: Liu et al. DNAzyme-mediated recovery of small recombinant RNAs from a 5S rRNA-derived chimera expressed in Escherichia coli. BMC Biotechnology 2010 10:85.